BioStock Investor Meeting: Interview with Lipum

Biopharmaceutical company Lipum is approaching clinical studies with the candidate SOL-116, which targets chronic inflammatory diseases such as rheumatoid arthritis. CEO Einar Pontén presented the company at the BioStock Investor Meeting in Stockholm and BioStock had the opportunity to interview Pontén about the upcoming clinical study and what distinguishes SOL-116 from today’s treatments.

See the full interview at biostock.se:

https://www.biostock.se/en/2022/09/biostock-investor-meeting-interview-with-lipum/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se